z-logo
open-access-imgOpen Access
Malaria Treatment Policy Change and Implementation: The Case of Uganda
Author(s) -
Miriam Nanyunja,
Juliet Nabyonga Orem,
Frederick Kato,
Mugagga Kaggwa,
Charles Katureebe,
Joaquim Saweka
Publication year - 2011
Publication title -
malaria research and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.726
H-Index - 15
eISSN - 2090-8075
pISSN - 2044-4362
DOI - 10.4061/2011/683167
Subject(s) - malaria , medicine , chloroquine , first line , drug resistance , sulfadoxine , economic growth , intensive care medicine , pyrimethamine , immunology , economics , biology , microbiology and biotechnology
Malaria due to P. falciparum is the number one cause of morbidity and mortality in Uganda where it is highly endemic in 95% of the country. The use of efficacious and effective antimalarial medicines is one of the key strategies for malaria control. Until 2000, Chloroquine (CQ) was the first-line drug for treatment of uncomplicated malaria in Uganda. Due to progressive resistance to CQ and to a combination of CQ with Sulfadoxine-Pyrimethamine, Uganda in 2004 adopted the use of ACTs as first-line drug for treating uncomplicated malaria. A review of the drug policy change process and postimplementation reports highlight the importance of managing the policy change process, generating evidence for policy decisions and availability of adequate and predictable funding for effective policy roll-out. These and other lessons learnt can be used to guide countries that are considering anti-malarial drug change in future

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom